The effect of pulmonary function testing on bleomycin dosing in germ cell tumours

F. T. Roncolato, M. Chatfield, B. Houghton, G. Toner, M. Stockler, D. Thomson, M. Friedlander, H. Gurney, M. Rosenthal, P. Grimison, The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP)

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background/Aim: The utility of pulmonary function testing (PFT) to detect bleomycin-induced pneumonitis is controversial. We describe its impact on bleomycin dosing in a phase 2 trial of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours. Methods: There were 12 planned weekly bleomycin doses for intermediate-risk and poor-risk disease and nine for good-risk disease. Clinical assessments, chest X-ray, diffusing capacity of lung for carbon monoxide (DLCO) and forced vital capacity (FVC) were performed bi-weekly. Bleomycin was ceased for predefined clinical/radiological evidence of pulmonary toxicity and a >25% reduction in DLCO or FVC. We determined doses planned, received and omitted and patients receiving all, ≥two-thirds, two-thirds of planned bleomycin doses. Results: Of 43 eligible patients, 30% had lung metastases. Of 471, 375 (80%) of planned bleomycin doses were received, and 30% received <two-thirds of their planned doses, all for reductions in DLCO. No patient developed other evidence of pulmonary toxicity. Patients with lung metastases were 1.5 times as likely to have a >25% reduction in DLCO (35 vs 24%, P = 0.4) and 1.5 times as likely to receive <two-thirds of their planned doses (35 vs 24%, P = 0.4). Patients who received less than full doses of bleomycin had worse outcomes if they were of good or poor prognosis. Conclusion: Asymptomatic reductions in DLCO caused 20% of bleomycin doses to be omitted and 30% of patients to receive <two-thirds of their planned doses. A 25% reduction in DLCO appears too cautious a threshold. Given the potential negative impact of this practice on anti-cancer effect, routine use of PFT to monitor for bleomycin toxicity should be questioned.

LanguageEnglish
Pages893-898
Number of pages6
JournalInternal Medicine Journal
Volume46
Issue number8
DOIs
Publication statusPublished - 1 Aug 2016
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Bleomycin
Lung
Vital Capacity
Lung Volume Measurements
indium-bleomycin
Etoposide
Carbon Monoxide
Cisplatin
Pneumonia
Thorax
X-Rays
Neoplasm Metastasis

Keywords

  • bleomycin
  • germ cell tumour
  • pulmonary function testing

Cite this

Roncolato, F. T., Chatfield, M., Houghton, B., Toner, G., Stockler, M., Thomson, D., ... The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP) (2016). The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. Internal Medicine Journal, 46(8), 893-898. https://doi.org/10.1111/imj.13158
Roncolato, F. T. ; Chatfield, M. ; Houghton, B. ; Toner, G. ; Stockler, M. ; Thomson, D. ; Friedlander, M. ; Gurney, H. ; Rosenthal, M. ; Grimison, P. ; The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP). / The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. In: Internal Medicine Journal. 2016 ; Vol. 46, No. 8. pp. 893-898.
@article{bb61a4ccd5634691993d4ded22fdba02,
title = "The effect of pulmonary function testing on bleomycin dosing in germ cell tumours",
abstract = "Background/Aim: The utility of pulmonary function testing (PFT) to detect bleomycin-induced pneumonitis is controversial. We describe its impact on bleomycin dosing in a phase 2 trial of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours. Methods: There were 12 planned weekly bleomycin doses for intermediate-risk and poor-risk disease and nine for good-risk disease. Clinical assessments, chest X-ray, diffusing capacity of lung for carbon monoxide (DLCO) and forced vital capacity (FVC) were performed bi-weekly. Bleomycin was ceased for predefined clinical/radiological evidence of pulmonary toxicity and a >25{\%} reduction in DLCO or FVC. We determined doses planned, received and omitted and patients receiving all, ≥two-thirds, two-thirds of planned bleomycin doses. Results: Of 43 eligible patients, 30{\%} had lung metastases. Of 471, 375 (80{\%}) of planned bleomycin doses were received, and 30{\%} received 25{\%} reduction in DLCO (35 vs 24{\%}, P = 0.4) and 1.5 times as likely to receive",
keywords = "bleomycin, germ cell tumour, pulmonary function testing",
author = "Roncolato, {F. T.} and M. Chatfield and B. Houghton and G. Toner and M. Stockler and D. Thomson and M. Friedlander and H. Gurney and M. Rosenthal and P. Grimison and {The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP)}",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/imj.13158",
language = "English",
volume = "46",
pages = "893--898",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell, Wiley",
number = "8",

}

Roncolato, FT, Chatfield, M, Houghton, B, Toner, G, Stockler, M, Thomson, D, Friedlander, M, Gurney, H, Rosenthal, M, Grimison, P & The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP) 2016, 'The effect of pulmonary function testing on bleomycin dosing in germ cell tumours', Internal Medicine Journal, vol. 46, no. 8, pp. 893-898. https://doi.org/10.1111/imj.13158

The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. / Roncolato, F. T.; Chatfield, M.; Houghton, B.; Toner, G.; Stockler, M.; Thomson, D.; Friedlander, M.; Gurney, H.; Rosenthal, M.; Grimison, P.; The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP).

In: Internal Medicine Journal, Vol. 46, No. 8, 01.08.2016, p. 893-898.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The effect of pulmonary function testing on bleomycin dosing in germ cell tumours

AU - Roncolato, F. T.

AU - Chatfield, M.

AU - Houghton, B.

AU - Toner, G.

AU - Stockler, M.

AU - Thomson, D.

AU - Friedlander, M.

AU - Gurney, H.

AU - Rosenthal, M.

AU - Grimison, P.

AU - The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP)

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background/Aim: The utility of pulmonary function testing (PFT) to detect bleomycin-induced pneumonitis is controversial. We describe its impact on bleomycin dosing in a phase 2 trial of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours. Methods: There were 12 planned weekly bleomycin doses for intermediate-risk and poor-risk disease and nine for good-risk disease. Clinical assessments, chest X-ray, diffusing capacity of lung for carbon monoxide (DLCO) and forced vital capacity (FVC) were performed bi-weekly. Bleomycin was ceased for predefined clinical/radiological evidence of pulmonary toxicity and a >25% reduction in DLCO or FVC. We determined doses planned, received and omitted and patients receiving all, ≥two-thirds, two-thirds of planned bleomycin doses. Results: Of 43 eligible patients, 30% had lung metastases. Of 471, 375 (80%) of planned bleomycin doses were received, and 30% received 25% reduction in DLCO (35 vs 24%, P = 0.4) and 1.5 times as likely to receive

AB - Background/Aim: The utility of pulmonary function testing (PFT) to detect bleomycin-induced pneumonitis is controversial. We describe its impact on bleomycin dosing in a phase 2 trial of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours. Methods: There were 12 planned weekly bleomycin doses for intermediate-risk and poor-risk disease and nine for good-risk disease. Clinical assessments, chest X-ray, diffusing capacity of lung for carbon monoxide (DLCO) and forced vital capacity (FVC) were performed bi-weekly. Bleomycin was ceased for predefined clinical/radiological evidence of pulmonary toxicity and a >25% reduction in DLCO or FVC. We determined doses planned, received and omitted and patients receiving all, ≥two-thirds, two-thirds of planned bleomycin doses. Results: Of 43 eligible patients, 30% had lung metastases. Of 471, 375 (80%) of planned bleomycin doses were received, and 30% received 25% reduction in DLCO (35 vs 24%, P = 0.4) and 1.5 times as likely to receive

KW - bleomycin

KW - germ cell tumour

KW - pulmonary function testing

UR - http://www.scopus.com/inward/record.url?scp=84983542643&partnerID=8YFLogxK

U2 - 10.1111/imj.13158

DO - 10.1111/imj.13158

M3 - Article

VL - 46

SP - 893

EP - 898

JO - Internal Medicine Journal

T2 - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

IS - 8

ER -

Roncolato FT, Chatfield M, Houghton B, Toner G, Stockler M, Thomson D et al. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. Internal Medicine Journal. 2016 Aug 1;46(8):893-898. https://doi.org/10.1111/imj.13158